Clinical Trial Update: Serum Hepatitis B Surface Antigen Levels to Guide the Stopping of Entecavir in HBeAg-negative Chronic Hepatitis B

View source ↗

Summary

A completed clinical trial evaluating whether Hepatitis B surface antigen levels can guide stopping entecavir in patients with HBeAg-negative chronic hepatitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ENTECAVIR (ENTECAVIR)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Chronic Hepatitis B | Status: COMPLETED